Saxagliptin for the treatment of diabetes - a focus on safety-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Saxagliptin for the treatment of diabetes - a focus on safety

Published:2016-03-21 Issue:5 Volume:15 Page:697-707
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Cernea Simona¹²,Cahn Avivit³,Raz Itamar³

Affiliation:

1. Department M3/Internal Medicine IV, University of Medicine and Pharmacy, Târgu Mureş, Romania

2. Diabetes, Nutrition and Metabolic Diseases, Emergency County Clinical Hospital, Târgu Mureş, Romania

3. Diabetes Unit, Department of Internal Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel

Publisher

Informa Healthcare

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1517/14740338.2016.1159675

Reference64 articles.

1. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

2. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes

3. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

4. DPP-4 inhibitors: pharmacological differences and their clinical implications

5. Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential inhibition of sildenafil and macitentan on saxagliptin metabolism;Toxicology and Applied Pharmacology;2024-05

2. A systematic review of astragaloside IV effects on animal models of diabetes mellitus and its complications;Heliyon;2024-03

3. Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus;Expert Opinion on Pharmacotherapy;2020-09-29

4. The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies;Expert Opinion on Drug Safety;2018-07-12

5. The safety of gliptins : updated data in 2018;Expert Opinion on Drug Safety;2018-03-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3